<DOC>
	<DOCNO>NCT00046696</DOCNO>
	<brief_summary>A study patient fail standard therapy . If dose limit toxicity patient receive cycle therapy evidence disease progression .</brief_summary>
	<brief_title>A Study NM-3 Administered Orally Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description>This non-randomized , open-label , Phase I study . A modified Fibonacci dose escalation use determine MTD subsequent Phase II trial . Study duration expect 12 18 month . Patients histological cytological diagnosis solid tumor fail standard therapy standard therapy exist enrol . If dose limit toxicity patient meet inclusion criterion none exclusion criterion protocol , receive cycle therapy evidence disease progression .</detailed_description>
	<criteria>Adult patient least 18 year age . All patient must advance solid tumor fail standard therapy standard therapy exist . Histological cytological diagnosis malignant solid tumor . Measurable nonmeasurable disease . Any chemotherapy , radiotherapy , major surgery least 4 week prior study entry ( 6 week nitrosoureas mitomycin C ) . Patients must recover toxic effect prior therapy . Karnofsky performance status index great equal 80 . Must adequate organ immune system function accord study design , obtain less equal 7days prior treatment NM3 . Female patient childbearing potential must negative serum pregnancy test within 7 day study enrollment . Men woman reproductive potential must use effective contraceptive method enrol study 3 month patient complete study . Patient must able swallow . Signed , write informed consent patient guardian . Estimated life expectancy least 12 week . Known sensitivity study drug analog . Treatment investigational therapy within precede 4 week . Patients hematological malignancy include leukemia , lymphoma , multiple myeloma . Active uncontrolled infection . Psychiatric disorder , alcohol chemical abuse would interfere consent followup . Uncontrolled congestive heart failure angina . Pregnancy lactation . Any severe concurrent disease , judge investigator , would make patient inappropriate entry study . Patients active gastrointestinal bleeding ulceration , unhealed wound active thrombosis . Patients anticoagulant therapy take aspirin , nonsteroidal antiinflammatory drug , unfractionated heparin , low molecular weight heparin , danaproid , thrombolytic agent , antiplatelet antibody , glycoprotein IIb , IIIa antagonists , H2 blocker , proton pump inhibitor . Brain leptomeningeal metastasis . Patients know HIV positive AIDSrelated illness . Patients history gastrointestinal bleeding varix , arteriovenous malformation , Osler Weber Rendu syndrome , polyp , prior surgery , gastric ulceration . Patients bleed associate coagulopathy surgery gastric ulceration bleed recurrence ulcer one year eligible study . Patients total accumulated doxorubicin equivalent dose 450 mg/m2 . Patients 1 risk factor , risk factor define one following ( 17 ) :1. prior anthracyclines large 300 mg/m2 doxorubicin equivalent.2.mediastinum/left breast irradiation . 3.history arterial hypertension ( systolic blood pressure great 140 diastolic blood pressure great 90 , receive antihypertensive treatment ) .4. obesity ( body mass index ( BMI ) [ 30 ] ) .5. diabetes mellitus ( fast plasma glucose level great 126 mg/dL American Diabetes Association ( ADA ) guideline ) .6. smoke ( smoke month prior study entry ) .7. hypercholesterolemia ( great 240 mg/dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Cancer Alternative Therapies</keyword>
	<keyword>Living Cancer</keyword>
</DOC>